Generic Eye Drop Recalls: Why You Don't Know What Your Patients Are Using
Since 2023, the FDA has issued a series of recalls and warnings involving over-the-counter artificial tears and lubricant eye drops sold at major retail chains across the United States. The scale of these recalls is significant — and for eye care practices managing dry eye patients, they raise an important question: do you know what your patients are using between visits?
A Pattern of Recalls
The wave of eye drop recalls began in early 2023 and has continued through 2025. Here is a summary of the major actions:
2023
- In February 2023, the FDA warned consumers not to use EzriCare Artificial Tears and Delsam Pharma Artificial Tears after contamination with a rare, drug-resistant strain of Pseudomonas aeruginosa was identified. The FDA received reports of serious eye infections, vision loss, and other severe outcomes linked to these products.
- In October and November 2023, the FDA warned against purchasing products manufactured by Kilitch Healthcare India Limited after investigators found insanitary conditions in the manufacturing facility and positive bacterial test results in critical drug production areas. More than 28 products sold under store brand names at CVS, Walmart, Rite Aid, and other major retailers were affected — including brands named Leader, Rugby, Velocity, and Equate.
2024
- In September 2024, Allergan recalled over 3 million tubes of Refresh P.M. and Refresh Lacri-Lube lubricant eye ointments due to a potential tube seal breach that could allow contamination.
- In December 2024, Alcon recalled a specific lot of Systane Lubricant Eye Drops Ultra PF Single Vials due to a complaint of fungal contamination.
- In late 2024, the FDA announced another recall involving eye drops possibly contaminated with fungus that could cause vision damage.
2025
- In March 2025, K.C. Pharmaceuticals of Pomona, California initiated a recall of more than 3.1 million bottles of artificial tears and lubricant eye drops sold under multiple brand names at CVS, Walgreens, Rite Aid, Kroger, H-E-B, and other major retailers. The recall was classified as Class II by the FDA, meaning the products may cause temporary or medically reversible adverse health consequences. Affected lots have expiration dates extending into May and October 2026 — meaning many of these bottles are still in patients' medicine cabinets right now.
- In May 2025, AvKARE voluntarily recalled over 75,000 cases of various eye care products manufactured by BRS Analytical Service due to FDA-identified deviations from current Good Manufacturing Practice (cGMP) regulations and a lack of sterility assurance.
The Core Problem: Patients Don't Know
Many of the recalled products are sold under generic or store brand names — "Dry Eye Relief Eye Drops," "Sterile Eye Drops," "Artificial Tears Sterile Lubricant Eye Drops" — that look nearly identical to safe products on the shelf. Patients cannot distinguish between a recalled lot and a compliant one without checking the specific lot number against the FDA's recall list.
Moreover, patients who purchased these products before the recall may still have them at home with no awareness that a recall has occurred. The March 2025 K.C. Pharmaceuticals recall affects bottles with expiration dates into 2026 — which means patients may continue using these products for months to come.
As an eye care provider, you may be seeing patients whose ocular surface symptoms are being influenced by the very drops they are using to treat them — without either of you knowing it.
What These Recalls Mean for Your Practice
The pattern of recalls over the past two years points to a systemic issue with certain segments of the generic eye drop manufacturing supply chain. Key concerns include:
- Insanitary manufacturing conditions — multiple manufacturers have been cited for facility violations that compromise sterility
- Bacterial contamination — some recalled products tested positive for bacteria in critical production areas
- Fungal contamination — at least one 2024 recall involved potential fungal contamination
- Sterility failures — several recalls were triggered by failure to meet sterility assurance standards, even without confirmed contamination
- Counterfeit products — in January 2025, the FDA flagged concerns about counterfeit eye drops entering the supply chain through online marketplaces
The Honest Conversation to Have Before Patients Leave
Here is the reality: once a patient walks out of your office, you cannot control what they pick up off the drugstore shelf. The generic aisle at CVS or Walgreens looks the same every time — same section, same types of packaging, same price points. But what is behind those labels has changed significantly over the past two years.
Patients who feel like they are doing the right thing by buying "artificial tears" may be using a product from a facility with known contamination issues, a recalled lot that is still sitting on shelves, or simply a formulation that does not perform at the level their eyes actually need.
The most important thing you can tell a dry eye patient before they leave your office is this: you cannot recommend the drugstore aisle. Not because every generic product is unsafe — but because you have no way of knowing which ones are, and neither do they.
Stop Leaving It to the Aisle. Dispense What You Trust.
The most effective way to take the guesswork out of your patients' dry eye regimen is to dispense products directly from your practice — products you have evaluated, you trust, and you stand behind.
When you hand a patient OASIS TEARS® PF and say "this is what I want you using," you close the loop. You know what they are using. You know it is preservative-free. You know the manufacturer. You know the formulation is appropriate for their condition. And patients who receive a direct recommendation from their doctor — and can buy it right there — are far more likely to use it consistently.
Oasis Medical offers a complete dry eye product ecosystem designed specifically for clinical practice settings:
- OASIS TEARS® PF — preservative-free lubricant eye drops with a proprietary formulation that soothes, lubricates, and relieves dry eye symptoms. Available in single-use containers and multi-use bottles. This is the product to put in your patients' hands.
- OASIS TEARS OMEGA® 3 — a high-purity omega-3 supplement with 1,000mg of DHA and EPA per softgel, formulated for dry eye support from the inside out.
- OASIS LID & LASH® — tea tree oil cleansing pads for gentle daily eyelid hygiene, addressing the Demodex and debris component of dry eye and MGD.
- OASIS REST & RELIEF® — a heat therapy eye mask with temperature-retaining beads for warm compress therapy at home.
This is a complete at-home dry eye regimen — tears, omega-3s, lid hygiene, and heat therapy — from a single trusted source. Instead of sending patients to figure it out themselves, you hand them the whole program.
The myOASIS Program: No Inventory Required
If stocking physical inventory feels like an operational burden, Oasis Medical has a solution for that too. The myOASIS program allows practices to recommend Oasis products directly to patients without keeping products on the shelf:
- You send the patient a direct ordering link
- Products ship directly to the patient's home
- No in-office inventory to manage
- No administrative overhead
- Patients get what you recommended, not what was on sale at Walgreens
It is a compliance and convenience tool that ensures your patients are actually using what you told them to use — not substituting with whatever generic they found at the drugstore.
Get Oasis Medical for Your Practice
Blue River Medical is the authorized Oasis Medical representative for Colorado, New Mexico, Wyoming, and Utah.
We can set you up with OASIS TEARS PF, the full Oasis dry eye product line, and access to the myOASIS patient ordering program. New practices can also request a free experiential workshop kit to sample Oasis products before making any purchase decisions.
Contact us at (877) 707-5688 or visit our Oasis Medical page to learn more.
Staying Current on Eye Drop Safety
The FDA updates its recall database regularly. Practices can monitor for new recalls at:
- FDA MedWatch: fda.gov/safety/medwatch
- FDA Recalls Database: fda.gov/safety/recalls-market-withdrawals-safety-alerts
For ongoing tracking of eye drop safety alerts, the Dry Eye Foundation maintains a running log at eyedropsafety.org.
*This post is for informational purposes only. For the most current recall information, consult the FDA's official recall database.
Tags
Have Questions About This Topic?
Our team is here to help you find the right solutions for your practice.
Contact Us